StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) stock

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.40+0.15 (+1.62%)

Close on Nov 17, 2026Market cap $558.21MP/E 10.1Yield –

Zevra Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Zevra Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was 42.8%. For fiscal 2025 it was 78.2%, against -446.9% the year before. The highest annual figure on record is 78.2% in fiscal 2025.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202578.2%+525.0
FY2024Dec 31, 2024-446.9%−279.2
FY2023Dec 31, 2023-167.7%+95.8
FY2022Dec 31, 2022-263.5%−233.6
FY2021Dec 31, 2021-29.9%+66.2
FY2020Dec 31, 2020-96.0%+95.0
FY2019Dec 31, 2019-191.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202622.1%−266.6
Q1 FY2026Mar 31, 2026104.6%+119.8
Q4 FY2025Dec 31, 202535.6%+332.4
Q3 FY2025Sep 30, 2025-2.1%+897.1
Q2 FY2025Jun 30, 2025288.7%+736.5
Q1 FY2025Mar 31, 2025-15.2%+470.1
Q4 FY2024Dec 31, 2024-296.8%−142.8
Q3 FY2024Sep 30, 2024-899.2%−541.1
Q2 FY2024Jun 30, 2024-447.9%−417.5
Q1 FY2024Mar 31, 2024-485.3%−69.2
Q4 FY2023Dec 31, 2023-154.0%−438.3
Q3 FY2023Sep 30, 2023-358.1%−127.9
Q2 FY2023Jun 30, 2023-30.4%+1819.0
Q1 FY2023Mar 31, 2023-416.2%−369.1
Q4 FY2022Dec 31, 2022284.4%+389.1
Q3 FY2022Sep 30, 2022-230.2%−140.7
Q2 FY2022Jun 30, 2022-1849.4%−1901.1
Q1 FY2022Mar 31, 2022-47.0%+38.0
Q4 FY2021Dec 31, 2021-104.7%+100.6
Q3 FY2021Sep 30, 2021-89.5%+66.8
Q2 FY2021Jun 30, 202151.8%+39.3
Q1 FY2021Mar 31, 2021-85.0%+190.5
Q4 FY2020Dec 31, 2020-205.2%+233.5
Q3 FY2020Sep 30, 2020-156.3%−183.0
Q2 FY2020Jun 30, 202012.4%–
Q1 FY2020Mar 31, 2020-275.4%–
Q4 FY2019Dec 31, 2019-438.7%–
Q3 FY2019Sep 30, 201926.7%–

More Zevra Therapeutics figures

See a number that looks wrong?